Ardy Arianpour, CEO & Co-Founder of Seqster, is a visionary genomics executive and serial entrepreneur in the biotech industry. Prior to starting Seqster, Ardy launched several clinical and consumer-based genetic tests as CCO of Pathway Genomics and SVP of Ambry Genetics, which sold to Konica Minolta for $1B in 2017. He is one of the main architects in launching the first commercial clinical exome sequencing test in 2011, establishing the value of next-gen sequencing in the clinic. As a key player in the 2013 landmark SCOTUS decision scrapping gene patents, Ardy played an instrumental role in expanding genetic testing access with the launch of BRCA testing benefiting patients and family members across the country. Ardy received his BS in Biological Sciences from University of California Irvine and an MBA from Marshall Goldsmith School of Management.